

Adelaide A Hebert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6782473/publications.pdf>

Version: 2024-02-01

56
papers

4,702
citations

257357

24
h-index

175177

52
g-index

57
all docs

57
docs citations

57
times ranked

4450
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	1.0	1,185
2	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	1.0	693
3	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 494-503.e6.	0.6	425
4	Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2008, 358, 241-251.	13.9	366
5	Insect repellents: Historical perspectives and new developments. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 865-871.	0.6	316
6	Insect repellents: An overview. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 243-249.	0.6	267
7	Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. <i>BMC Pediatrics</i> , 2016, 16, 75.	0.7	137
8	Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 641-649.e5.	0.6	110
9	Dermatologic and Dental Aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. <i>JAMA Dermatology</i> , 2014, 150, 1095.	2.0	93
10	Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne. <i>JAMA Dermatology</i> , 2020, 156, 621.	2.0	78
11	Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 316-323.	0.6	76
12	Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications. <i>Journal of Clinical Medicine</i> , 2015, 4, 884-917.	1.0	74
13	Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex. <i>JAMA Dermatology</i> , 2018, 154, 773.	2.0	71
14	Pediatric psoriasis: Evolving perspectives. <i>Pediatric Dermatology</i> , 2018, 35, 170-181.	0.5	66
15	Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. <i>Pediatric Dermatology</i> , 2016, 33, 380-387.	0.5	61
16	Bacterial Resistance and Impetigo Treatment Trends: A Review. <i>Pediatric Dermatology</i> , 2012, 29, 243-248.	0.5	59
17	Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 128-138.e2.	0.6	56
18	Primary Pediatric Hyperhidrosis: A Review of Current Treatment Options. <i>Pediatric Dermatology</i> , 2008, 25, 591-598.	0.5	53

#	ARTICLE	IF	CITATIONS
19	Current and Emerging Medical Therapies for Primary Hyperhidrosis. <i>Dermatology and Therapy</i> , 2017, 7, 25-36.	1.4	45
20	Insect repellents: An updated review for the clinician. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 123-130.	0.6	40
21	Patient impact and economic burden of mild-to-moderate atopic dermatitis. <i>Current Medical Research and Opinion</i> , 2018, 34, 2177-2185.	0.9	37
22	Focal Epithelial Hyperplasia: Heck Disease. <i>Pediatric Dermatology</i> , 1993, 10, 245-251.	0.5	33
23	Diagnostic Features, Differential Diagnosis, and Treatment of Subungual Osteochondroma. <i>Pediatric Dermatology</i> , 1994, 11, 39-41.	0.5	31
24	Ozenoxacin: a review of preclinical and clinical efficacy. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 159-168.	2.0	30
25	A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 593-604.	3.3	26
26	Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 135-145.	3.3	26
27	Special Considerations for Children with Hyperhidrosis. <i>Dermatologic Clinics</i> , 2014, 32, 477-484.	1.0	25
28	Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. <i>Pediatric Dermatology</i> , 2019, 36, 89-99.	0.5	22
29	Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 641-655.	3.3	21
30	A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis. <i>Pediatric Dermatology</i> , 2015, 32, 609-617.	0.5	17
31	Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial. <i>Drugs in R and D</i> , 2018, 18, 295-302.	1.1	17
32	Desonide foam 0.05%: Safety in children as young as 3 months. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 334-340.	0.6	14
33	The cutaneous manifestations of tuberous sclerosis complex. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2018, 178, 321-325.	0.7	13
34	Evaluation of psychological well-being and social impact of atrophic acne scarring: A multinational, mixed-methods study. <i>JAAD International</i> , 2022, 6, 43-50.	1.1	13
35	Understanding Patient Experience With Hyperhidrosis: A National Survey of 1,985 Patients. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 392-396.	0.4	13
36	Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study. <i>Pediatric Dermatology</i> , 2020, 37, 490-497.	0.5	12

#	ARTICLE	IF	CITATIONS
37	The Use of TNF± Inhibitors in Treating Pediatric Skin Disorders. <i>Paediatric Drugs</i> , 2020, 22, 311-319.	1.3	9
38	African Tick-Bite Fever after a Game-Hunting Expedition. <i>New England Journal of Medicine</i> , 2015, 372, e14.	13.9	8
39	Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis. <i>International Journal of Women's Dermatology</i> , 2020, 6, 331-333.	1.1	8
40	Primary hyperhidrosis in children: A review of therapeutics. <i>Pediatric Dermatology</i> , 2021, 38, 561-567.	0.5	8
41	Clinical and bacteriological efficacy of twice daily topical retapamulin ointment 1% in the management of impetigo and other uncomplicated superficial skin infections. <i>International Journal of Women's Dermatology</i> , 2015, 1, 13-20.	1.1	7
42	Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to <math>\infty</math> Years. <i>Paediatric Drugs</i> , 2022, 24, 175-183.	1.3	7
43	A new therapeutic horizon in diaper dermatitis: Novel agents with novel action. <i>International Journal of Women's Dermatology</i> , 2021, 7, 466-470.	1.1	6
44	A comparative review of current topical antibiotics for impetigo. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-7.	1.0	5
45	Neurocristopathy Syndrome: Review of Four Cases. <i>Pediatric Dermatology</i> , 1990, 7, 87-92.	0.5	4
46	Association between industry funding and academic productivity among dermatology faculty. <i>Journal of the American Academy of Dermatology</i> , 2019, 85, 733-735.	0.6	3
47	Therapeutic challenges in managing pediatric psoriasis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 314-318.	1.1	3
48	Daily Moisturization for Atopic Dermatitis: Importance, Recommendations, and Moisturizer Choices. <i>Journal for Nurse Practitioners</i> , 2021, 17, 920-925.	0.4	3
49	Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis. <i>Pediatric Dermatology</i> , 2022, 39, 55-60.	0.5	3
50	Skin Barrier Repair in Eczema: A Review of Current Understanding of Pathophysiology and Treatment. <i>Current Dermatology Reports</i> , 2012, 1, 115-122.	1.1	2
51	Cutaneous manifestations of orthostatic intolerance syndromes. <i>International Journal of Women's Dermatology</i> , 2021, 7, 471-477.	1.1	2
52	Laboratory Evaluation of the Child with Recalcitrant Eczema. <i>Dermatologic Clinics</i> , 1994, 12, 109-121.	1.0	1
53	Ozenoxacin, a Novel, Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients with Impetigo: Phase III Clinical Trials Pooled Analysis Results. <i>SKIN the Journal of Cutaneous Medicine</i> , 0, 1, s102.	0.1	1
54	Confirmatory Psychometric Evaluation of the Axillary Sweating Daily Diary: A Validated Patient-Reported Outcome Measure to Assess Axillary Hyperhidrosis Sweating Severity. <i>SKIN the Journal of Cutaneous Medicine</i> , 0, 1, s94.	0.1	1

#	ARTICLE	IF	CITATIONS
55	The case of the dog and the blue light. Journal of the American Academy of Dermatology, 2018, 79, 782-784.	0.6	0
56	Overcoming challenges in management of atopic dermatitis: Role of oxidative stress in the pathogenesis and treatment target of atopic dermatitis (ROAD). , 0, 2, 47.		0